Skip to main content
. 2022 Apr 19;40(22):2447–2457. doi: 10.1200/JCO.21.02389

FIG 1.

FIG 1.

Definition of primary efficacy end point. Freedom from transfusion represented an absence of any combination of RBC transfusions and/or platelet transfusions for at least 4 weeks. Transfusion of any type was not an inclusion criterion; however, freedom from transfusion was included in the end point because it is a clinical benefit. GVHD, graft versus host disease; LDH, lactate dehydrogenase; MAGIC, Mount Sinai Acute GVHD International Consortium; TMA, thrombotic microangiopathy.